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Introduction: The skeleton is generally the primary, and sometimes the only, site
of metastasis in patients with advanced solid tumors. Bone metastases are the
most frequent cause of cancer-related pain and the origin of severe morbidity
in patients. Among the treatment options available for the prevention of
skeletal-related events (SREs) associated with bone metastasis, zoledronic acid,
an antiresorptive treatment from the group of bisphosphonates, is currently
the standard of care in this setting.
Areas covered: Zoledronic acid, together with denosumab (a monoclonal
antibody against the receptor activator of nuclear factor kappa B ligand), is
the most frequent approach for the prevention of cancer-related events in
skeleton. This paper reviews several trials evaluating the efficacy of denosu-
mab in comparison with zoledronic acid in patients with solid osteotropic
tumors. In this setting of skeleton-invading cancers, denosumab was demon-
strated to be superior to zoledronic acid in preventing or delaying SREs. In
comparison with zoledronic acid, denosumab significantly delayed the time
to first SRE by 17%.
Expert opinion: Current research on denosumab is addressed to prove the
immunomodulator effect of this agent in humans. Other avenue of research
is focused on its antitumor activity observed in some Phase III trials.
Keywords: bone metastasis, breast cancer, denosumab, prostate cancer, skeletal-related events,
solid tumors
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1. Introduction
Bone metastases are a complication in a wide range of malignancies. The skeleton is
a frequent site of metastases, with it generally being the first, and sometimes the
only, site in patients with osteotropic advanced tumors. Bone metastases cause con-
siderable morbidity. It is well known that some types of tumors present a more pre-
dictable pattern of spread than others. Tumors associated with skeletal metastases
and bone loss are mainly prostate cancer, breast cancer and multiple myeloma.
Metastases to the bone may produce fractures, hypercalcemia, pain and a decrease
in the mobility and performance status of the patient [1].
Skeletal metastases are usually divided into osteolytic lesions, in which the resorp-
tion of the normal bone is the predominant process, and osteoblastic lesions, in
which the predominant process includes the deposition of new bone. However,
this division is not absolute and many lesions may result from a mixed process. In
patients with breast cancer as well as in patients with multiple myeloma, bone
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metastases are predominantly osteolytic lesions, whereas oste-
oblastic lesions are commonly detected in patients with pros-
tate cancer [2-5].
Bone loss in cancer patients is a multifactorial process. The
understanding of the pathophysiological mechanisms
involved in this process has provided new approaches to these
events. One important emerging therapy includes, as part of
its mechanism, the blocking of the receptor activator of
nuclear factor kappa B (NF-kB) ligand (RANKL) to its natu-
ral receptor (RANK). This inhibits osteoclastogenesis and,
thus, reduces bone resorption and interferes with mechanisms
that stimulate osteoblastic bone formation, while inhibiting
osteoclastic resorption [6].
2. Incidence and consequences of bone
metastasis
The prevalence of bone metastasis in cancer patients is partic-
ularly high. Skeletal metastases are detected in 65 -- 75% of
patients with advanced prostate cancer and this percentage is
even higher in patients who eventually die from the disease.
The issue may become even worse due to the fact that the
administration of androgen deprivation therapy for advanced
prostate cancer promotes bone loss and therefore, skeletal-
related events (SREs) [7]. SREs are defined as pathological
fractures, spinal cord compression and radiotherapy for bone
and bone surgery and are associated with increased morbidity
and mortality in patients with bone metastases. Bone metasta-
ses are also present in ~ 65 -- 75% of advanced breast cancer
patients [8]. As in patients with prostate cancer, bone loss in
breast cancer patients is the result of cancer and its treatment.
As an example, aromatase inhibitors, which are drugs com-
monly used for the treatment of estrogen receptor-positive
breast cancer, are agents that increase the risk of osteoporo-
sis [9,10]. In addition, breast cancer is most likely to affect
postmenopausal women. In these patients, there is an addi-
tional high age- and gender-related risk for bone loss and frac-
ture associated with the estrogen decline, which is even more
pronounced due to the administration of aromatase inhibitors
to these patients [11]. Moreover, women with chemotherapy-
induced ovarian failure have an increased risk for
osteoporosis. Table 1 shows the incidence of bone metastasis
by tumor type.
The normal mechanism of bone metabolism in patients
with cancer can be significantly disrupted by treatment and
metastasis. Both events especially alter the process of osteo-
clastic bone resorption. There are at least four factors driving
the development of bone metastases: cancer cells, osteoblasts,
osteoclasts and mineralized bone matrix, which releases
growth factors. However, the main characteristic of all meta-
static bone lesions is the deregulated increase of bone resorp-
tion by osteoclasts in a process similar to that leading to
osteoporosis. Malignant lesions in bone are, thus, classified
as i) osteolytic, when the main process is bone destruction;
ii) osteoblastic, when the predominant process is the forma-
tion of new, weaker bone; or iii) mixed lesions. The incidence
of pathological fractures is higher in osteolytic lesions [12,13].
The median survival for patients from the time of diagnosis
of bone metastasis varies among different tumor types. In the
case of breast and prostate cancer, survival is measured in
years. In contrast, in the case of lung cancer, the survival
from the time of diagnosis of bone metastasis is measured in
months (Table 1) [14,15]. Nevertheless, coexisting nonosseous
metastases are also important in prognosis. Thus, in patients
with advanced breast cancer who present a first relapse to
the bone, the probability of survival is influenced by the sub-
sequent development of extraosseous metastases [16,17].
Skeletal metastasis is the cause of severe morbidity in
patients with advanced cancer. Pain, hypercalcemia, patholog-
ical bone fractures, neurological deficits due to the compres-
sion of nerves by the collapse of vertebrae and reduced
activity associated with bone metastases all lower a patient’s
quality of life [18]. A patient with bone metastatic disease expe-
riences, on average, a SRE every 3 -- 6 months. The occur-
rence of these events is not regular but becomes more
frequent as the disease becomes more extensive [19].
Common sites of bone metastases associated with pain are
the base of skull, vertebrae, pelvis and femur. Hypercalcemia
had been frequently detected in patients with cancer and
bone metastases; however, this symptom has become a rare
event since the advent of antiresorptive therapy to treat bone
metastases [20]. Hypercalcemia is the result of the bone
destruction characteristic of osteolytic metastases. Secretion
of humoral and paracrine factors by tumor cells increases oste-
oclast activity and proliferation as well as the production of
markers of bone turnover [21,22]. It is likely that tumor cells
exploit the same molecules to induce proliferation and acti-
vate osteoclasts to favor the implantation of metastatic cells
and their spread in bone tissue. The osteoclastogenic factors
produced by tumor cells include parathyroid hormone-related
Article highlights.
. To date, zoledronic acid has represented the most
important tool to reduce the risk of SREs in patients
with bone metastases.
. Denosumab targets the RANKL pathway, which is
essential for the activation of bone resorption
by osteoclasts.
. Denosumab provided an alternative to bisphosphonates
for control of bone metastases-related events.
. Denosumab has been studied in various solid tumors,
including breast cancer and prostate cancer.
. The advantages of denosumab over bisphosphonates are
with regard to both the efficacy in term of delayed time
to first SRE and in reduced rates of acute phase
reactions and renal adverse effects.
. Interesting findings about denosumab with regard to
the potential immunomodulatory effects and antitumor
activity are suggested.
This box summarizes key points contained in the article.
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protein (PTHrP) and RANKL. In addition, the kidney may
be involved in the development of malignant hypercalcemia,
due to volume depletion. Moreover, the action of parathyroid
hormone-related peptide increases the reabsorption of cal-
cium, thus further elevating the serum calcium levels. Left
untreated, hypercalcemia results in the deterioration of renal
function and of the mental status of the patient, and death
may result from cardiac arrhythmias and renal failure.
With regard to pathological bone fractures, the destruction
of bone primarily results in microfractures, which leads to
chronic pain in patients. Subsequently, long bone fractures
may occur, causing a higher grade of disability, while the
compression of the spinal cord is another SRE associated
with bone metastases. Radiation is an effective therapy for
metastatic bone disease. This therapy not only diminishes
tumor mass and promotes bone healing of osteolytic lesions
but also leads to pain relief. Pain is thought to be relieved as
a secondary mechanism to tumor shrinkage and also due to
the inhibition of chemical pain mediators [23]. Spinal cord
compression constitutes a severe medical emergency. Pain,
in this case, is frequently localized in the area of the tumor
and the radicular pain gets worse at night. However, it may
also radiate down a limb or around the chest or abdomen.
The majority of patients presenting spinal cord compression
describe weakness, paralysis, numbness, distal anesthesia, uri-
nary retention, incontinence and impotence. However, if the
lesion occurs in the conus medullaris, patients may present dys-
function of the bladder, rectum and genitalia. With regard to
spinal instability, this event occurs in 10% of the patients with
advanced cancer who present back pain. Surgery is often
required in order to relieve such pain [19].
3. Prevention of SREs in patients with
advanced cancer
Among the treatment options available for the prevention of
SREs associated with bone metastases, bisphosphonates,
such as zoledronic acid, are one of the therapeutic groups
that are more extensively used in this setting. Denosumab, a
monoclonal antibody, exerts its efficacy through the suppres-
sion of osteoclast formation via a mechanism of action differ-
ent from that exploited by bisphosphonates.
3.1 Role of bisphosphonates
Currently, it is well known that bisphosphonates can reduce
bone pain, alongside the use of analgesics and bone irradia-
tion, and are a reliable solution for the underlying cause of
SREs and malignant osteolysis, delaying the onset and reduc-
ing the incidence of these events [24-26]. There are two types of
bisphosphonates with different mechanisms of action [27].
Bisphosphonates are preferentially incorporated into sites of
active bone remodeling. They inhibit hydroxyapatite break-
down with subsequent effective suppression of bone resorp-
tion. Bisphosphonates also function to limit both osteoblast
and osteocyte apoptosis. The first type is non-nitrogen-con-
taining bisphosphonates, such as clodronate, which are
metabolized into cytotoxic compounds by osteoclasts and
the second type is nitrogen-containing bisphosphonates.
This group includes zoledronic acid, pamidronate and ibandr-
onate, which inhibit the mevalonate pathway, leading to oste-
oclast apoptosis. Both types of bisphosphonates may be
administered for the prevention and treatment of SREs asso-
ciated with bone metastases in cancer patients.
At the present time, zoledronic acid is considered the cur-
rent standard of care for preventing or delaying SREs in can-
cer patients who have bone metastases [28].
3.2 Role of denosumab
Denosumab is a fully monoclonal antibody that binds and
neutralizes RANKL. Through this binding, denosumab
inhibits osteoclast function as well as bone resorption and
local bone destruction.
3.2.1 Preclinical data and mechanism of action
of denosumab
Tumor necrosis factor (TNF) receptor superfamily member
11B, also known as osteoprotegerin (OPG), is a decoy factor
for RANKL. By its union with RANKL, OPG inhibits
NF-kB, which is crucial for cell survival and differentiation.
The significance of the RANKL/RANK pathway has been dem-
onstrated in knockout experiments in which either RANK-/- or
RANKL-/- mice presented important defects in bone resorption,
lymph node formation and B-cell development [29]. In contrast,
OPG-/- mice developed osteoporosis and hypercalcemia,
according to the results of another study [30]. Thus, the balance
between RANKL and its receptor RANK, as well as its decoy
factor OPG, is essential for bone and calcium homeostasis.
Not unexpectedly, this balance is shifted toward bone resorp-
tion in several human diseases, such as cancer.
Denosumab has been produced in transgenic mice by the
deletion and replacement of their murine immunoglobulin
genes with human orthologs [31]. As both OPG and denosu-
mab have a similar mechanism of action, OPG has been
Table 1. Incidence of bone metastasis according to
tumor type and median survival [6,8].
Tumor type Incidence of
bone metastasis (%)
Median survival
from diagnosis of
bone metastasis
(months)
Multiple myeloma 90 -- 100 NR
Prostate cancer 65 -- 75 12 -- 53
Breast cancer 65 -- 75 19 -- 25
Bladder cancer 40 6 -- 9
Lung cancer 30 -- 40 6 -- 7
Kidney cancer 20 -- 25 12
Thyroid cancer 60 48
NR: Not reported.
Target therapy for bone metastasis
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used as a surrogate for the study of RANKL inhibition in ani-
mal models. Through these tests, it was demonstrated that
OPG importantly reduces the amount of osteoclasts in bone
lesions arising from direct intratibial infection of cancer cells
from human prostate cancer in immunodeficient mice [32].
Experiments in rats have demonstrated that a single injection
of OPG results in a rapid, sharp reduction in the proportion
of bone surfaces occupied by osteoclasts, that is, a 95% reduc-
tion within 12 h after its administration. This reduction grad-
ually returned to normal values from days 10 to 30 after
the injection.
However, denosumab has several differences in terms of
selectivity over OPG. Denosumab does not bind to TNF-
related apoptosis-inducing ligand (TRAIL) or other TNF
family members, such as TNF-a, TNF-b and CD40 ligand,
whereas TRAIL binding has been observed with OPG [33,34].
Denosumab targets the RANKL pathway. This pathway is
essential for osteoclast differentiation, activation and function
and its expression is thought to be induced by products of
cancer cells, such as the PTHrP [35].
Figure 1 shows the role of RANKL, the receptor RANK and
the decoy factor OPG in the control of bone metabolism and
the mechanism of action of denosumab. In bone lytic lesions
related to cancer, this balance is shifted in favor of RANKL
expression and the decrease in OPG expression. Generally,
cancer cells upregulate RANKL expression on stromal osteo-
blasts by the secretion of regulatory cytokines and hormones.
In some instances, cancer cells can express RANKL and
directly activate osteoclasts [32,36].
RANKL is expressed not only by osteoblasts but also by
activated T cells and synoviocytes [37]. RANK is a receptor
expressed by monocytes, macrophages and dendritic cells.
The RANK--RANKL interaction has been demonstrated to
be involved in immunomodulation in different animal mod-
els [38]. RANKL is expressed on a number of T and B cells,
and CD4+CD25+ T cells have been shown to be regulated
by the RANK--RANKL signaling system. Denosumab, as an
inhibitor of the RANK--RANKL signaling, has the potential
to be an immunomodulator. Studies with mouse keratino-
cytes suggest that blocking RANKL in mice decreases the
number of regulatory T cells in skin, thus leading to an
increased inflammatory response.
3.2.2 Efficacy data of denosumab
In Table 2, the main efficacy data of denosumab in compari-
son with zoledronic acid from randomized trials is
summarized.
3.2.2.1 In advanced breast cancer
A randomized, double-blind study was conducted by
Stopeck et al. to test the efficacy of denosumab in
2046 patients with advanced breast cancer and metastases to
bone [39]. These patients were randomly assigned to receive
subcutaneous denosumab (120 mg) plus intravenous placebo
or intravenous zoledronic acid (4 mg) plus subcutaneous pla-
cebo every 4 weeks. Randomization was stratified by prior
SRE, prior oral bisphosphonate use, current chemotherapy
and geographical region (Japan or other regions). All patients
Tumor cell
RANKL
RANK
Activation
Osteoclast
Osteoclast
precursor cell
Osteoblastic stromal cellHematopoietic stem cell
Development
Cytokines
Growth factors
Hormones
OPG
Denosumab
Figure 1. Illustration of mechanism of action of denosumab.
Dashed lines: Inhibition routes; OPG: Osteoprotegerin; RANK: Receptor activator of nuclear factor kappa B; RANKL: RANK ligand.
C. Rolfo et al.
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were recommended to take calcium and vitamin D supple-
ments. Denosumab was demonstrated to be superior to zole-
dronic acid in delaying the time to first on-study SRE
(hazard ratio [HR] 0.82; 95% CI: 0.71 -- 0.95;
p < 0.001 for noninferiority and p = 0.01 for superiority).
In addition, denosumab was superior to zoledronic acid in
the time to first and subsequent on-study SREs, with a rate
ratio of 0.77 (95% CI: 0.66 -- 0.89; p = 0.001 for superiority).
Additionally, bone turnover marker levels showed a greater
reduction in the denosumab treatment arm than in the
control arm.
Similar values were observed in terms of overall survival
(OS), disease progression and adverse event (AE) rates of any
grade, as well as in the incidence of severe AEs (SAEs). How-
ever, acute phase reactions and renal AEs were more frequent
in patients treated with zoledronic acid, whereas hypocalcemia
was frequently observed in patients treated with denosumab.
With regard to osteonecrosis of the jaw (ONJ), this AE was
not differentially observed in any of the study arms, occurring
in 2% of the patients in the denosumab arm in comparison
with 1.4% of the patients in the zoledronic acid arm
(p = 0.39). Hence, denosumab was shown to be superior to
zoledronic acid in delaying as well as preventing SREs in
patients with advanced breast cancer and metastasis to bone.
Denosumab also demonstrated a good safety profile. Unlike
patients treated with zoledronic acid, patients treated with
denosumab did not require renal monitoring. Denosumab
was demonstrated to be superior to zoledronic acid in delaying
or preventing SREs in patients with breast cancer and
metastasis to bone. This drug was also well tolerated.
3.2.2.2 In advanced prostate cancer
The treatment of bone metastases in patients with castration-
resistant prostate cancer (CRPC) was tested in a randomized,
double-blind, Phase III study [40]. The randomization of
1904 patients was stratified by previous SREs, prostate-
specific antigen concentration and chemotherapy for prostate
cancer administered within 6 weeks prior to the randomiza-
tion. Patients were randomized to receive 120 mg of subcu-
taneous denosumab plus intravenous placebo or 4 mg of
intravenous zoledronic acid plus subcutaneous placebo every
4 weeks. All patients were recommended to take supplements
of calcium and vitamin D. Median time to first on-study
SRE was significantly longer in the denosumab arm
(20.7 months) than in the zoledronic acid arm (17.1 months;
HR = 0.82; 95% CI: 0.71 -- 0.95; p = 0.0002 for noninfer-
iority and p = 0.008 for superiority). In terms of time to first
and subsequent on-study SREs, patients treated with denosu-
mab showed 494 SREs in comparison with 584 SREs
detected in the zoledronic acid arm. The SREs rate ratio
was 0.82 (95% CI: 0.71 -- 0.94; p = 0.004 unadjusted and
p = 0.008 adjusted for multiplicity).
Thus, 1888 of 1904 patients were included in the safety
profile assessment. SAEs were recorded in 63% of the patients
treated with denosumab and 60% of the patients treated with
zoledronic acid. Some differences between arms were found in
the frequency of certain AEs. With regard to hypocalcemia, a
higher number of events were observed in patients treated
with denosumab compared with those treated with zoledronic
acid (13 vs 6%, respectively; p < 0.0001). However, ONJ was
not frequent in any of the treatment groups (2 vs 1%, respec-
tively; p = 0.09). Thus, denosumab was superior to zoledronic
acid in the prevention of SREs in patients with CRPC and
skeleton metastatic disease.
3.2.2.3 In advanced solid tumors and multiple myeloma
A randomized, double-blind, Phase III study evaluated the
efficacy and safety of denosumab in comparison with zole-
dronic acid in patients with multiple myeloma or solid
tumors, excluding breast and prostate cancer, who presented
metastases to the bone [41]. Patients were randomly assigned
to receive a subcutaneous injection of denosumab (120 mg)
Table 2. Main efficacy data of denosumab and zoledronic acid in cancer patients with bone metastasis.
Study No. Type of patients Treatment Time to first on-study SRE Time to first and subsequent
on-study SREs
Stopeck et al. [39] 1026 Advanced breast
cancer
Denosumab HR: 0.82; 95% CI: 0.71 -- 0.95;
p < 0.001 for noninferiority and
p = 0.01 for superiority
RR: 0.77; 95% CI: 0.66 -- 0.89;
p = 0.001, adjusted superiority1020 Zoledronic acid
Fizazi et al. [40] 950 Advanced prostate
cancer
Denosumab HR: 0.82; 95% CI: 0.71 -- 0.95;
p = 0.0002 for noninferiority
and
p = 0.008 for superiority
RR: 0.82; 95% CI: 0.71 -- 0.94;
p = 0.008 adjusted superiority951 Zoledronic acid
Henry et al. [41] 886 Advanced multiple
myeloma or solid
tumors, excluding
breast and prostate
cancer
Denosumab HR: 0.84; 95% CI: 0.71 -- 0.98;
p = 0.0007 for non-inferiority;
for superiority,
p = 0.03 unadjusted
and p = 0.06 adjusted
RR: 0.90; 95% CI: 0.77 -- 1.04;
p = 0.14 adjusted superiority890 Zoledronic acid
CI: Confidence interval; HR: Hazard ratio; RR: Rate ratio; SRE: Skeletal-related event.
Target therapy for bone metastasis
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plus an intravenous infusion of placebo or an intravenous
infusion of zoledronic acid (4 mg) plus a subcutaneous injec-
tion of placebo every 4 weeks. Patients were stratified by
tumor type, namely non-small-cell lung cancer (NSCLC),
multiple myeloma or other type of tumor. A description of
the existing primary tumor types in this clinical trial is pre-
sented in Table 3. Patients with multiple myeloma were lim-
ited to 10% of the study population. Daily supplementation
of calcium and vitamin D was recommended to every patient.
Last, monitoring of creatinine clearance was carried out in
patients treated with zoledronic acid.
Denosumab was noninferior to zoledronic acid in delaying
the time to first on-study SRE (HR = 0.84; 95% CI:
0.71 -- 0.98; p = 0.0007 for noninferiority and p = 0.06 for
superiority), resulting in a 16% reduction in this ratio. The
median time to first on-study SRE was 20.6 months for deno-
sumab in comparison with 16.2 months for zoledronic acid
(p = 0.03 unadjusted and p = 0.06 adjusted for multiplicity).
Time to first and subsequent SREs analysis resulted in a rate
ratio of 0.90, when denosumab was compared with zoledronic
acid (95% CI: 0.77 -- 1.04; p = 0.14), which did not achieve
statistical significance. OS and disease progression values were
similar in both groups of treatment. In an ad hoc analysis
examining the effect of denosumab relative to zoledronic
acid in the subset of patients with multiple myeloma, an
assessment in terms of OS demonstrated an HR of
2.26 (95% CI: 1.13 -- 4.50); However, denosumab has not
been approved for the treatment of patients with multiple
myeloma and bone metastases.
However, patients treated with denosumab presented a
higher suppression of bone turnover markers than patients
treated with zoledronic acid. Between baseline and week 13,
urinary N-telopeptides (uNTx):creatinine ratio decreased by
76% in patients treated with denosumab and by 65% in
patients treated with zoledronic acid (p < 0.001). Bone-
specific alkaline phosphatase decreased by 37% in patients
treated with denosumab and by 29% in patients treated
with zoledronic acid (p < 0.001). These bone markers have
different origin. In particular, NTx is related to osteoclast
activity and bone-related alkaline phosphatase is a conse-
quence of osteoblast activation.
In terms of safety profile, both treatment groups experi-
enced similar overall AEs and SAEs (66% in patients treated
with zoledronic acid and 63% in patients treated with denosu-
mab). In addition, infectious AE rates were similar: 40 and
41%, respectively. Hypocalcemia occurred as expected at
higher frequency in patients treated with denosumab than in
those with zoledronic acid (10.8 vs 5.8%), although no clini-
cal consequences were observed in these patients. Regarding
ONJ, similar rates were obtained with both treatments as
well as similar cumulative incidence rates after 1, 2 or 3 years
of treatment (p = 1). Among patients who developed ONJ,
risk factors associated with this AE were also observed. These
risk factors were present in 91% of patients receiving zole-
dronic acid and 70% of patients receiving denosumab.
Within the first 3 days after the administration of the first
dose, AEs associated with acute phase reactions occurred in
14.5% of the patients treated with zoledronic acid and 6.9%
of the patients treated with denosumab. There were no dose
adjustments or withholding due to renal function in patients
treated with denosumab. In spite of dose adjustments or treat-
ment withholdings in the zoledronic acid arm, renal AEs
occurred in 11% of patients treated with zoledronic acid
and 8% of patients receiving denosumab. Hence, this new
agent was demonstrated to be noninferior, with a trend
toward superiority, to zoledronic acid in the prevention or
delay of first on-study SRE in patients with advanced solid
tumors or multiple myeloma and metastases to bone.
Henry et al. also conducted a subanalysis of this trial in
1597 patients with exclusively solid tumors and bone metasta-
sis [42]. In this subanalysis, the delay achieved by denosumab
in the time to the first on-study SRE was higher than with
zoledronic acid (HR = 0.81; 95% CI: 0.68 -- 0.96;
p < 0.020). In time to first and subsequent SREs, denosumab
showed more favorable result than zoledronic acid
Table 3. Types of tumors included in the Henry et al.
trial [41].
Type of tumor Denosumab,
n = 890
n (%)
Zoledronic
acid,
n = 886
n (%)
All,
n = 1776
n (%)
NSCLC 350 (40) 352 (40) 702 (40)
Multiple myeloma 87 (10) 93 (10) 180 (10)
Renal 70 (8) 85 (10) 155 (9)
Small-cell lung cancer 61 (7) 48 (5) 109 (6)
Bladder 28 (3) 35 (4) 63 (4)
Rectal 25 (3) 35 (4) 60 (3)
Colon 30 (3) 29 (3) 59 (3)
Unknown primary 31 (4) 27 (3) 58 (3)
Head and neck 24 (3) 19 (2) 43 (2)
Cervix 18 (2) 25 (3) 43 (2)
Gastric 19 (2) 16 (2) 35 (2)
Non-Hodgkin lymphoma 17 (2) 15 (2) 32 (2)
Soft tissue sarcoma 18 (2) 13 (2) 31 (2)
Endometrial 16 (2) 11 (1) 27 (2)
Other 14 (2) 11 (1) 25 (1)
Esophageal 10 (1) 15 (2) 25 (1)
Neuroendocrine 14 (2) 10 (1) 24 (1)
Carcinoid melanoma 12 (1) 11 (1) 23 (1)
Ovarian 12 (1) 7 (0.8) 19 (1)
Thyroid 7 (0.8) 6 (0.7) 13 (0.7)
Pancreatic 3 (0.3) 8 (0.9) 11 (0.6)
Renal, pelvis and ureter 4 (0.5) 5 (0.6) 9 (0.5)
Gastrointestinal, other 4 (0.5) 4 (0.4) 8 (0.5)
Hodgkin’s disease 5 (0.6) 2 (0.2) 7 (0.4)
Liver 1 (0.1) 4 (0.4) 5 (0.3)
Anal 1 (0.1) 2 (0.2) 3 (0.2)
Testicular 2 (0.2) 1 (0.1) 3 (0.2)
Skin, squamous cell 2 (0.2) 0 (0.0) 2 (0.1)
Biliary tract 1 (0.1) 1 (0.1) 2 (0.1)
EPAR: European Public Assessment Report.
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(HR = 0.85; 95% CI: 0.72 -- 1; p < 0.05). Results for OS
(HR = 0.92; 95% CI: 0.81 -- 1.05; p = 0.21) and disease pro-
gression (HR = 0.96; 95% CI: 0.85 -- 1.08; p = 0.5) were sim-
ilar in both treatment arms. Regarding the safety profile,
although in both arms the incidence of overall AEs was simi-
lar, patients treated with zoledronic acid presented a higher
rate of AEs potentially associated with renal toxicity (10.3%)
than patients treated with denosumab (7.1%). In addition,
more acute phase reactions were observed in the zoledronic
acid arm (14.8%) than in the denosumab arm (7.1%). In con-
trast, the incidence of severe (grades 3 or 4) hypocalcemia was
more frequently observed with denosumab than with zole-
dronic acid (4.4 vs 1.8%, respectively). Last, the incidence
of ONJ was rarely observed in both treatment arms.
In a recent systematic review with meta-analysis on com-
parison between denosumab and bisphosphonates, the former
had lower incidence of renal toxicity (rate ratio [RR] = 0.76;
95% CI: 0.59 -- 0.98) and acute phase reactions
(RR = 0.42; 95% CI: 0.37 -- 0.49). No differences of CTCAE
v4.0 grade 3 AEs, ONJ, new cancers and the incidence of
infections were observed between the two kinds of drugs.
Denosumab had similar risk to bisphosphonates in the occur-
rence of ONJ, but an increased trend in the denosumab group
was noted (1.8 vs 1.3%, respectively) [43].
3.2.2.4 Integrated analysis of three Phase III trials
Three identically designed Phase III pivotal trials were evalu-
ated through a predetermined integrated analysis [44]. The
integrated analysis was conducted to assess the delay or the
prevention effect of denosumab on SREs in comparison
with zoledronic acid in patients with several types of osteo-
tropic cancers. A total of 5723 patients with different diagno-
ses of cancer such as breast, prostate and other type of solid
tumors or multiple myeloma were included, representing
2988 SREs (1360 for denosumab; 1628 for zoledronic acid).
Denosumab was superior to zoledronic acid in delaying the
time to first on-study SRE by 17% (median time to first SRE:
27.7 vs 19.5 months: HR = 0.83; 95% CI: 0.76, 0.90;
p < 0.0001 both for noninferiority and superiority). In terms
of delay of the time to first and subsequent on-study SREs,
denosumab was also superior to zoledronic acid by 18%
(HR = 0.82; 95% CI: 0.75, 0.89; p < 0.001 for superiority).
In both treatment arms, values were similar in terms of overall
disease progression (HR = 1.02; 95% CI: 0.95 -- 1.08;
p = 0.63) and survival (HR = 0.99; 95% CI: 0.91 -- 1.07;
p = 0.71).
Regarding the safety profile, similar percentages of AEs as
well as SAEs were reported in both treatment groups. How-
ever, hypocalcemia was reported in 9.6% of patients treated
with denosumab and in 5% of patients treated with zole-
dronic acid. Data regarding ONJ did not differ significantly
in both arms (1.8% with denosumab vs 1.3% with zoledronic
acid; p = 0.13). Interestingly, ONJ was resolved in 29.7% for
zoledronic acid and 40.4% for denosumab. Regarding hypo-
calcemia, this AE was reported in 9.6% of patients treated
with denosumab and 5% of patients treated with zoledronic
acid. AEs related to renal toxicity had 2.6% higher incidence
in patients treated with zoledronic acid than in those treated
with denosumab. Finally, AEs related with acute phase reac-
tions to the drug were reported by 8.7 vs 20.2% of patients
treated with denosumab and zoledronic acid, respectively.
Hence, denosumab was superior to zoledronic acid in delay-
ing or preventing SREs in a wide range of cancer types with
bone metastases.
In another integrated analysis of the three pivotal trials car-
ried out by Cleeland et al., patients completed the Brief Pain
Inventory (range: 0 -- 10) and several evaluations of pain
severity were carried out throughout the analysis. Time to
clinically significant pain worsening was delayed in patients
treated with denosumab in comparison with patients treated
with zoledronic acid (181 vs 169 days, respectively;
HR = 0.92; 95% CI: 0.86 -- 0.99; p = 0.026). Patients treated
with denosumab, with no pain or with mild pain at baseline,
showed a more prolonged time to moderate or severe pain in
comparison with patients treated with zoledronic acid
(p = 0.0002). Time to pain improvement was similar in
both groups of patients (p = 0.844). Hence, denosumab pre-
vents clinically relevant increase in pain in comparison with
zoledronic acid in all the tumor types tested. In addition,
denosumab was similar in terms of pain relief to zoledronic
acid [45].
3.3 Other treatments of SREs in patients with
advanced cancer
The pharmacological approach for the treatment of painful
osseous metastases follows the World Health Organization
analgesic stepladder guidelines to pain relief [46,47]. Analgesic
agents that may play a role in this approach include acetamin-
ophen, non-steroidal anti-inflammatory drugs (NSAIDs),
cyclooxygenase-2 (COX-2) inhibitors, antidepressants,
anticonvulsants, muscle relaxants, a-2 adrenergic agonists,
n-methyl-d-aspartate receptor antagonists and opioids or
opioid-like analgesic agents. The use of traditional, non-
selective NSAIDs in cancer-related bone pain is under scru-
tiny due to lack of robust evidence about their ability to
relieve pain in metastatic bone disease. However,
COX-2 inhibitors may be of greater therapeutic potential,
partially due to their antiangiogenic properties [48,49]. With
regard to opioid analgesics, while long-acting opioids are
administered for constant or baseline pain, rapid-onset
opioids address breakthrough pain, characteristic of advanced
bone metastases. An inconvenience with the use of opioids is
that this type of drug may be overused, abused or misused in
chronic cancer [50]. An anticonvulsant, gabapentin, has been
demonstrated to be useful in the treatment of neuropathic
cancer pain [51], as well as having adjuvant properties, syner-
gistic with opioid analgesics [52].
The administration of external beam radiotherapy induces
the removal of cancer cells from the bone and facilitates the
Target therapy for bone metastasis
Expert Opin. Biol. Ther. (2014) 14(1) 21
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Fr
an
ci
s A
 C
ou
nt
w
ay
 L
ib
ra
ry
 o
f M
ed
ic
in
e 
on
 1
2/
16
/1
3
Fo
r p
er
so
na
l u
se
 o
nl
y.
repair of the bone with osteoblasts [53]. External beam radio-
therapy may lead to improvements in analgesia as well as to
functional improvements and reduction of the risk of bone
fracture. It has been demonstrated that 80% of patients
receiving radiotherapy to the bone experience partial or com-
plete pain relief within 10 -- 14 days after the initiation of
therapy [54]. On the other hand, radiopharmaceutical therapy
is an approach which provides several advantages over conven-
tional external beam radiotherapy, such as i) intravenous
administration; ii) usefulness in the treatment of multiple, dif-
fuse sites with mild bone marrow depression and iii) fewer
AEs associated with the administration of radiopharmaceuti-
cals in comparison with radiotherapy [55]. The experimental
radiopharmaceutical radium-223 chloride, also named alphar-
adin, is a new type of targeted cancer therapy for bone metas-
tases. Alpharadin is under development and is currently being
studied for the treatment of patients with advanced prostate
cancer and bone metastases via a-radiation [56]. Interventional
techniques also give optimal results in patients with painful
bone metastases. The most frequently performed techniques
for patients with painful bone metastases are vertebral abla-
tion, subdivided into radiofrequency ablation and cryoabla-
tion, and vertebral augmentation procedures, which are
carried out in patients with spinal metastases and vertebral
compression fractures. The most frequent vertebral augmen-
tation procedures are percutaneous vertebroplasty and percu-
taneous kyphoplasty [57]. Recently the Phase III Alpharadin
in Symptomatic Prostate Cancer Patients study compared
the efficacy and safety of radium-223 versus placebo in
patients with CRPC and bone metastases. It showed an
improvement of OS by radium-223 [58].
4. Recommendations issued in treatment
guidelines
With regard to breast cancer, the National Comprehensive
Cancer Network (NCCN) guidelines have recognized the
superiority of denosumab in comparison with zoledronic
acid in terms of time to the occurrence of SREs, as a second-
ary end point of a randomized, active controlled trial [59]. As
a result, these guidelines open the way for women with
metastatic breast cancer to bone, who are candidates for
bisphosphonates therapy, to be considered for treatment with
denosumab.
Moreover, the guidelines address recommendations in
order to prevent ONJ, such as dental examination prior to
treatment with bisphosphonates or denosumab, as well as
avoiding dental procedures as far as possible. Frequent meas-
urements of calcium, phosphate and magnesium serum levels
may be prudent in this patient population. The NCCN
guidelines recommend denosumab or zoledronic acid in
patients with prostate cancer who are positive for bone metas-
tasis [60]. Denosumab, zoledronic acid and alendronate are
also recommended for patients undergoing treatment with
an androgen deprivation therapy for prostate cancer. In
addition, the NCCN guidelines recognized that both denosu-
mab and zoledronic acid have been shown to prevent disease-
related skeletal complications, such as fracture, spinal cord
compression, or the need for surgery or radiotherapy to
bone in men with castration-recurrent prostate cancer. How-
ever, denosumab was shown to be superior to zoledronic
acid in the prevention of SREs. The guidelines recommend
the monitoring of patients for the detection of hypophospha-
temia and hypocalcemia. In this patient population, denosu-
mab may be administered to men with impaired renal
function, including patients undergoing hemodialysis. How-
ever, these patients present a higher risk of severe hypocalce-
mia and hypophosphatemia; hence, frequent measurements
of calcium and phosphate levels are required. In these
patients, hypocalcemia should be corrected before starting
denosumab, and serum calcium monitoring is required in
patients treated with denosumab and recommended in
patients treated with zoledronic acid. The NCCN guide-
lines [61] recommend the administration of bisphosphonates
or denosumab for the treatment of bone metastases in
NSCLC patients. According to the NCCN guidelines [59-61],
frequent monitoring for the detection of hypocalcemia is rec-
ommended in patients with prostate cancer, breast cancer or
NSCLC. Supplemental calcium and vitamin D treatment is
also recommended in order to prevent hypocalcemia in these
three populations receiving either denosumab or
zoledronic acid.
In the recently published guidelines of the Spanish Society
of Medical Oncology (SEOM) [62], the superiority of denosu-
mab in comparison with zoledronic acid in preventing or
delaying SREs in breast and prostate cancer was described.
Moreover, SEOM guidelines also describe the noninferiority
of denosumab in comparison with zoledronic acid in the
treatment of bone metastases in other solid tumors and mye-
loma. SEOM guidelines highlight the convenient subcutane-
ous administration of denosumab and the fact that no dose
adjustment is required in cases of renal impairment. These
guidelines also state the fact that denosumab significantly
increased the median metastasis-free survival in patients with
high risk non-metastatic prostate cancer, according to results
of a Phase III study of denosumab in comparison with
placebo [63].
The updates of the American Society of Clinical Oncology
(ASCO) guidelines are conducted according to an evidence-
based pre-established protocol [64]. Denosumab was first
added to the recommendations issued by ASCO guidelines
in the update published in March 2011 for the treatment of
patients with breast cancer and bone metastasis.
5. Conclusion
This review has highlighted the new clinical results about the
superiority of denosumab over bisphosphonates in preventing
SREs in cancer patients with bone metastases. The relevant
findings relative to this comparison could be explained by
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the known mechanisms of action of denosumab, which are
different from those observed for bisphosphonates. In fact,
these effects are related to RANKL inhibition. However, this
mechanism of action could also clarify both the immunomod-
ulatory and antitumor effects of denosumab. Denosumab has
already gained the indication for SRE prevention in cancer
patients with bone metastases. The adverse effects of denosu-
mab are similar to those observed for bisphosphonates, except
for the renal impairment and acute phase reactions, which
arise less frequently in the patients treated with denosumab.
Future researches should focus on antitumor activity of this
drug to also improve OS as some initial findings suggested.
6. Expert opinion
Bone metastases represent a complication in a wide range of
malignancies. In fact, the skeleton is generally the first, and
sometimes the only, site of metastases in patients with an
advanced tumor. Bone metastases cause considerable morbid-
ity in patients. In addition, they are the most frequent cause of
cancer-related pain. Owing to the improvement of therapies
and survival rates in cancer patients, bone metastases are now-
adays more frequently detected in patients. In this review, two
types of agents administered for the prevention and treatment
of cancer-related effects on bone have been reviewed.
Bisphosphonates, particularly zoledronic acid, are reported
as the best-known antiresorptive drugs. Denosumab, a mono-
clonal antibody which exerts its activity through the suppres-
sion of osteoclasts formation, provides a new approach for the
prevention of cancer-related effects. Denosumab has been
demonstrated to be superior to zoledronic acid in delaying
and preventing SREs in a wide range of cancer types with
bone metastases. In addition, in lung cancer, denosumab has
demonstrated an improvement in survival compared with
zoledronic acid.
With regard to the safety profile of both drugs, ONJ was an
infrequent AE in patients treated with any of the agents. In
patients treated with denosumab or with zoledronic acid, no
significant differences in ONJ rates were found. However,
hypocalcemia was more frequent in patients receiving denosu-
mab. Thus, calcemia levels should be monitored in patients
treated with denosumab to avoid severe symptomatic hypo-
calcemia that may include fatal cases [65]. On the other
hand, renal monitoring was more frequently required in
patients treated with zoledronic acid, with subsequent dose
adjustment in some patients.
Last, in the recent update of ASCO guidelines, denosumab
has been included for the treatment of patients with breast
cancer and bone metastasis. The NCCN guidelines recog-
nized that both denosumab and zoledronic acid have been
shown to prevent disease-related skeletal complications, such
as fracture, spinal cord compression, or the need for surgery
or radiotherapy to bone in men with castration-recurrent
prostate cancer, and also that denosumab was shown to be
superior in the prevention of SREs in comparison with zole-
dronic acid in this patient population.
The SEOM guidelines also recognized the superiority of
denosumab in comparison with zoledronic acid in patients
with breast and prostate cancer with metastases to the bone.
In addition, SEOM guidelines highlight the convenient sub-
cutaneous administration of denosumab and the non-
requirement for dose adjustment in patients with renal
impairment. They also highlight the higher metastasis-free
survival detected in patients with non-metastatic prostate can-
cer, according to results of a Phase III trial comparing denosu-
mab versus placebo. Hence, denosumab represents a potential
new treatment for the management of bone metastases across
a broad range of solid tumor types.
The findings about new target drugs in metastatic prostate
cancer allow us to contemplate that antitumor activity is
strictly linked with the control of bone resorption and related
symptoms. As previously found for zoledronic acid, denosu-
mab also seems to have direct antitumor effects. This consid-
eration is deduced by both preclinical findings and clinical
outcome changes (i.e., OS) by denosumab. We propose that
these effects could be a consequence of RANK and RANKL
expression in tumor cells. The expression of these molecules
in cancer cells suggests the hypothesis that the
RANK--RANKL pathway has further functions beyond the
regulation of bone resorption. Specific studies are needed to
support this hypothesis. Denosumab should be tested in can-
cer cell lines, experimental models with tumor-bearing mice
and translational studies evaluating the activity on metastases
different from bone-related ones, and functional imaging
could help to clarify these results.
Denosumab is actually a promising drug, which offers bet-
ter opportunities in reducing the risk of SREs than bisphosph-
onates with less adverse effects. However, we could suppose
that in the future years several studies will clarify the antitu-
mor effects and could help in identifying the better combina-
tion of denosumab with other drugs.
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